EuroBiotech Report—Celgene-Immatics, AstraZeneca, Immunicum, Adaptimmune and InDex

Map of Europe

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week in Germany, where Immatics reeled in $75 million from Celgene. The deal gives Celgene the chance to option three T-cell programs—and Immatics a shot at generating $1.5 billion in milestones. Elsewhere, AstraZeneca paid Swedish Orphan Biovitrum $95 million for a FDA priority review voucher. Immunicum’s allogeneic dendritic cell vaccine failed to improve on Pfizer's Sutent. Adaptimmune formed a preclinical research pact. InDex Pharmaceuticals presented phase 2b ulcerative colitis data. And more. — Nick Taylor
1. Celgene pays Immatics $75M to work on solid tumor cell therapies

Celgene has paid Immatics $75 million (€68 million) upfront to collaborate on the development of anti-cancer adoptive cell therapies. The deal gives Celgene the chance to opt in to T-cell treatments for solid tumor programs once they reach candidate selection.

2. AstraZeneca pays Sobi $95M for priority review voucher

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

AstraZeneca has struck a $95 million (€86 million) deal to buy a FDA priority review voucher from Swedish Orphan Biovitrum. The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.

3. Immunicum's vaccine fails to beat Pfizer's Sutent in phase 2

Immunicum’s allogeneic dendritic cell vaccine ilixadencel has failed to better the 18-month survival rate achieved by Pfizer’s Sutent in a phase 2 metastatic renal cell carcinoma trial. As of the cutoff, 63% of patients in the ilixadencel arm were alive compared to 66% in the Sutent cohort.
4. Adaptimmune pens backloaded deal to access T-cell tech

Adaptimmune has struck a deal to access Noile-Immune Biotech’s technology for improving cancer cell therapies. The collaboration, which could cost Adaptimmune $312 million all told, is expected to move a candidate into human testing in 2021. 
5. InDex's topical ulcerative colitis drug hits goal in phase 2b

A phase 2b trial of InDex Pharmaceuticals’ ulcerative colitis drug has met its primary endpoint. The trial linked use of the highest dose of the topical TLR9 agonist to a 15% improvement in the clinical remission rate over placebo.
And more articles of note>> 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.